| Naftidrofuryl vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.56 [0.07 4.40] | p=1.00 | 0 | 450 | 2 | NIQOL germany,NCIS, | | stroke (fatal and non fatal) | 1.03 [0.02 52.67] | p=1.00 | 0 | 181 | 1 | NCIS, | | Revascularization | no data | | All cause death | 0.39 [0.10 1.64] | p=1.00 | 0 | 798 | 4 | NIQOL germany,Clyne,NIQOL belgium,NCIS, | | Treatment related complication | 0.85 [0.43 1.68] | p=1.00 | 0 | 401 | 2 | NIQOL belgium,NCIS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| naftidrofuryl IV vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Amputation | no data | | All cause death | 0.67 [0.04 11.49] | p=1.00 | 0 | 40 | 1 | Meehan, | | Treatment related complication | 0.68 [0.01 36.35] | p=1.00 | 0 | 37 | 1 | Meehan, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| naftidrofuryl IV vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Amputation | no data | | All cause death | 0.15 [0.01 2.87] | p=1.00 | 0 | 235 | 1 | D'Hooge D, | | Treatment related complication | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| naftidrofuryl IV vs prostacyclin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Amputation | no data | | All cause death | no data | | Treatment related complication | 0.08 [0.00 1.73] | p=1.00 | 0 | 29 | 1 | Negus, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
